참고문헌
- Academy of Medical of Malaysia (2010). Clinical Practice Guidelines(CPGs). Management Breast Cancer. http://www.moh.gov.my/cpgs.
- Afshar Moghaddam N, MahsoniP, Rajabi P, Pooyan Tabibi A (2008). Correlation of Her-2/Neu and Tp53 Expressions with Clinicopathologic Characteristics in Infiltrative Ductal Breast Carcinomas. Iranian J Pathology, 3, 75-80
- Albanell J, Andreu X, et al (2009). Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol, 11, 363-75 https://doi.org/10.1007/s12094-009-0370-6
- Alizadeh SA, Moshfeghi K, Kalantari M, Ebrahimi Kh (2010). Lymph-node involvement and tumor markers in patients with breast Cancer. Arak Med University J, 12, 44-50
- Amouzegar Hashemi F, Alaleh A, Kazemian A, Haddad P (2010). Local recurrence after breast conserving surgery in breast cancer: a study in Cancer Institute, Tehran. Tehran University Med J, 67, 863-9
- Antonio C Wolff, M Elizabeth H Hammond, et al (2007). American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast Cancer. J Clin Oncol, 25, 118-45
- Arafah M (2012). Correlation of hormone receptors with her 2/ neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia. Turk Patoloji Derg, 28, 38-43
- Attarian H, Pirzadeh A, Rezvani H, et al (2011). Clinicopathologic manifestations of Iranian patients with breast cancer. Pak J Med Sci, 27, 182-5
- Barberis M, Pellegrini C, Cannone M, et al (2008). Quantitative PCR and HER2 testing in breast cancer a technical and cost-effectiveness analysis. Am J Clin Pathol, 129, 563-70 https://doi.org/10.1309/1AKQDQ057PQT9AKX
- Carlson RW, Moench SJ,One author et al (2006). HER2 testing in breast cancer: NCCN task force report and recommendations. J Natl Compr Canc Netw, 4,1-22 https://doi.org/10.6004/jnccn.2006.0001
- Chandarlapaty S, Modi Sh, Sloan-Kettering M (2011). Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs? J Clin Oncol, 10;29(23):3111-Ahn ER, https://doi.org/10.1200/JCO.2011.36.4091
- Dendukuri N, Khetani K, McIsaac M, Brophy J (2007). Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ, 176, 1429-33 https://doi.org/10.1503/cmaj.061011
- El-A Helal T, Khalifa A, Kamel AS (2000). Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt. Anticancer Res, 20, 2145-50
- Elkin EB, Weinstein MC, Winer EP, et al (2004). HER-2 testing and Trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol, 22, 854-63 https://doi.org/10.1200/JCO.2004.04.158
- Ensani F, Kargar M, Davanloo M, Irvanloo G, Khazaeipour Z (2010). Comparison between Immunohistochemistry and Chromogenic in Situ Hybridization Method in Assessment of HER-2 Status in Breast Cancer. Iranian J Surgery, 7, 8-16
- Espinosa AB, Tabernero MD, Garcia-Macias MC, et al (2003). Her-2/neu Gene Amplification in Familial vs Sporadic Breast Cancer. Am J Clin Pathol, 120, 917-27 https://doi.org/10.1309/5H778W5K75CMM03W
- Fattahi MG, Mojtahedi Z, Karimaghaee N, et al (2009). Analysis of BRCA1 and BRCA2 mutations in Southern Iranian breast cancer patients. Arch Iran Med, 12, 584-7
- Ghaffari SR, Sabokbar T, Dastan J, Rafati M, Moossavi Sh (2011). Her 2 Amplification Status in Iranian Breast Cancer Patients: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridisation (FISH). Asian Pac J Prev, 12, 1031-4.
- Gown AM, Goldstein LC, Barry TS, et al (2008). High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol, 21, 1271-7 https://doi.org/10.1038/modpathol.2008.83
- Gown AM (2008). Current issues in ER and HER2 testing by IHC in Breast Cancer. Mod Pathol, 21, 8-15 https://doi.org/10.1038/modpathol.2008.34
- Halimi M, Aghbali A, Tabrizi D, Olad Sahebmadarek E (2011). Expression of epidermal Growth Factor Receptor Tyrosine Kinase Family in Fine Needle Aspiration and permanent Specimens of Invasive Lobular and Ductal Breast cancer. Pak J Biol Sci, 14, 584-9 https://doi.org/10.3923/pjbs.2011.584.589
- Harirchi I, Kolahdoozan S, Karbakhsh M, et al (2011).Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncology. 22, 93-7 https://doi.org/10.1093/annonc/mdq303
- Homaei-shandiz F, Ghavam naseri MR, Sharifi N, et al (2006). Evaluation of the Relationship Between Human Epidermal Growth factor receptore-2/neu (c-erbB-2) Amplification and pathologic Grading in Patterns with Breast Cancer. Saudi Med J, 27, 1810-4
- Hudis CA, MD (2007). Trastuzumab -Mechanism of Action and Use in Clinical Practice. N engl J med, 357, 39-51 https://doi.org/10.1056/NEJMra043186
- Jeremy St. J. Thomas (2009). Quality Assurance in Her-2 Testing-Redefining the Gold Standard. Clin Chem, 55, 1265-7 https://doi.org/10.1373/clinchem.2009.126219
- Kadivar M, Askarzadeh P, Shayanfar N, Sadeghipour AR, Bahraminejad M (2009). Interpretation of immunohistochemistry results of HER2/neu expression in invasive breast cancer: evaluation of Interobserver and Intraobserver Agreement. Razi J Medical Science, 16, 147-55
- Kadivar M, Esmaili A, Joolaee A (2010). evaluation of microvessel density and vascular endothelial growth factor in invasive breast carcinoma via immunohistochemistry and their correlation with clinicopathologic parameters. Razi J Medical Sci, 16, 46-56
- Kadivar M, Rezaee M, Jadidfard R, Joulaee A (2010). Evaluation of histopathology and biologic markers in premenopausal (under 40 years) and postmenopausal (over 60 years) women with breast cancer in hazrat-e-rasoul and atieh hospitals. Razi J Medical Sci, 17, 49-57
- Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE (2010). Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. a SEER analysis. Kakarala et al. BMC Cancer, 10, 2-8 https://doi.org/10.1186/1471-2407-10-2
- Kuo SJ, Wang BB, Chang CS et al (2007). Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/NEU status in Taiwanese breast cancer patients. Taiwan J Obstet Gynecol, 46, 146-53 https://doi.org/10.1016/S1028-4559(07)60008-4
- Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidi JP (2008). Multiple-treatments meta-analysis of chemotherapyand targeted therapies in advanced breast cancer. J Natl Cancer Inst, 100, 1780 -91 https://doi.org/10.1093/jnci/djn414
- Mechanized system of breast cancer management Iran (2011). http://bcancer.ir. (Persian)
- Mirmalek S.A, Tirgary F, Alizadeh HR (2005). Study and comparison between malignant breast tumors and related surounding benign tissue about HER-2 Receptor Persistence. Iranian J surgery, 13
- Mirzaei HR, Sabahat A, Nasrollahi F, Mohammadi-Yeganeh L (2010). Correlation between ER, PR, HER2 receptors and prognostic factors in breast cancer. Pejouhandeh, 15, 152-6
- Mofid B, Jalali NMR, Kian L, Zayeri F (2004). Association of HER2 With prognostic factors of breast cancer. J the Faculty of Med, 28, 29-32
- Moghadaszadeh M, Nikanfar AR, Hemati MR, Gharibi B, Sardashti S (2010). Interaction between Her-2 and Hormone Receptor in Breast Cancer. International J Hematology Oncology and Stem cells Res, 4, 14-16
- Mohammadizadeh F, Ghasemibasir HR, Rajabi P, et al (2009). Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma. Cancer Biomark, 5, 1-8 https://doi.org/10.3233/CBM-2009-0551
- Montgomery KG, Gertig DM, Baxter SW, et al (2003). The HER2 I655V Polymorphism and Risk of Breast Cancer in Women_ Age 40 Years. Cancer Epidemiology, Biomarkers and Prevention, 12, 1109-11
- Moore S (2012). Heart failure in a breast cancer survivor. Oncol Nurs Forum, 39, 147-50 . https://doi.org/10.1188/12.ONF.147-150
- Moradi-Marjaneh M, Homaei-Shandiz F, Shamsian SAA, Eftekhar-Zadeh Mashhadi I, Hedayati-Moghadam MR (2008). Correlation of HER2/neu Over Expression, p53 Protein Accumulation and Steroid Receptor Status with Tumor Characteristics: An Iranian Study of Breast Cancer Patients. Iranian J Publ Hlth, 37, 19-28
- Mousavi SM, Montazeri A, Mohagheghi MA et al (2007). Breast cancer in iran: an epidemiological review. Breast J, 13, 383-91 https://doi.org/10.1111/j.1524-4741.2007.00446.x
- Naeem M, Nadim Khan, Aman Z et al (2008). Pattern of breast cancer: experience at lady reading hospital, peshawar. J Ayub Med Coll Abbottabad. 20, 22-5
- Naghshvar F, Torabizade ZH, Emadian O, Zareh A, Ghahramani M (2007). Status of estrogen, progesterone receptors and HER-2/neu expression in invasive breast cancer. J Gorgan university Medical Sci, 8, 65-68
- Pourzand A, Fakhree MBA, Hashemzadeh Sh, Halimi M, Daryani A (2011). Hormone Receptor Status in Breast Cancer and its Relation to Age and Other Prognostic Factors. Breast Cancer, 5,87-92
- Rabiee Hashemi SM, Rabiee Hashemi S (2008). HER-2, P53 and hormonal receptors protein expression as predictive factors in breast cancer prognosis. Chin J Clin Oncol, 5, 413-7 https://doi.org/10.1007/s11805-008-0413-8
- Saatee S, Afrakhteh M, Sadrolhefazi B (2006). High Prevalence of HER-2/ neu overexpression among Iranian women with breast cancer: True or False? Breast J, 12 ,499-501 https://doi.org/10.1111/j.1075-122X.2006.00315.x
- Salimi M, Mozdarani H, Majidzadeh K (2012). Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients. Med Oncol, 29, 1502-9 https://doi.org/10.1007/s12032-011-0043-5
- Shahriari Ahmadi A, Ghavamzadeh A, Amiri N et al (2005). Clinical, biological and pathological characteristics of breast cancer patients at the taleghani university hospital in kermanshah, Iran. IJHOBMT, 2, 6-11
- Shamsalinia A, Keihanian Sh, Ghaffari F, Mansore Saravi M, Najafi Ashtian M (2010). Association between expression of her-2/neu gene and estrogen receptors, progesterone receptors and p53 gene among female with primary breast cancer. The Iranian J Obstetrics, Gynecology and Infertility, 13, 43-48
- Sirati F, Ghahhari.A, Alavi N (2009). Determination of the Prevalence of Prognostic factors(HER-2/neu, P53, PR, ER) in breast cancer and assessment of their correlation with each others and age and menopause state of patients. Iranian J of breast disease, 1, 24-31
- Smith I, Procter M, et al (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 396, 29-36
- Vogel CL (2012). Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat, 131, 371-83 https://doi.org/10.1007/s10549-011-1781-y
- World Bank (2010). Gross domestic product World Development Indicators database. http://www.worldbank.org.; Accessed 1 July 2011
- Yip CH, Smith RA, et al (2008). Guideline implementation for breast healthcare in low-and middle-income countries. Cancer, 113, 2221-43 https://doi.org/10.1002/cncr.23844
피인용 문헌
- gene status and association of clinicopathological variables with it in invasive breast cancer patients vol.124, pp.5, 2016, https://doi.org/10.1111/apm.12518